Table 3.
Comparison between cerebellar irAE and PCA
| Features | Cerebellar irAE | PCA | p Value |
|---|---|---|---|
| Sex, n (%) | N = 35 | N = 15 | |
| Female | 10 (29) | 10 (67) | 0.01 |
| Male | 25 (71) | 5 (33) | |
| Abs, n (%) | N = 31 | N = 15 | |
| Ab positivity | 15 (48) | 9 (60) | > 0.05 |
| High risk Abs | 7 | 8 | < 0.05 |
| [Anti-Yo] | [3] | [6] | [< 0.05] |
| [Anti-Hu] | [2] | [1] | [> 0.05] |
| UNCA | 2 | 0 | > 0.05 |
| Other Abs | 6 | 1 | > 0.05 |
| Ab negativity | 16 (52) | 6 (40) | |
| Tumor type, n (%) | N = 35 | N = 15 | |
| NSCLC | 12 (34) | 1 (7) | > 0.05 |
| SCLC | 9 (26) | 1 (7) | > 0.05 |
| Lung cancer (NSCLC and SCLC) | 21 (60) | 2 (13) | < 0.01 |
| Gynecological and breast cancer | 1 (3) | 5 (42) | < 0.01 |
| Symptoms, n (%) | N = 32 | N = 15 | |
| “isolated cerebellar ataxia” | 13 (37) | 1 (7) | < 0.05 |
| ataxia and dysarthria | 6 (17) | 6 (40) | > 0.05 |
| ataxia and ocular involvement | 4 (11) | 5 (33) | > 0.05 |
| ataxia and (ocular involvement or dysarthria) | 10 (28) | 11 (73) | < 0.01 |
| “pancerebellar syndrome” | 9 (26) | 3 (20) | > 0.05 |
| Immune-modulating therapy, n (%) | N = 35 | N = 15 | |
| Yes | 33 (94) | 10 (67) | < 0.05 |
| None | 2 (6) | 5 (33) | |
| Neurological outcome, n (%) | N = 35 | N = 13 | |
| Improvement | 25 (71) | 5 (33) | < 0.05 |
| No improvement/worsening | 10 (29) | 8 (53) |
Abbreviations Ab, antibody; irAE, immune-related adverse event; n, number; N, total number of patients considered as per data availability; NSCLC, non-small cell lung cancer; PCA, paraneoplastic cerebellar ataxia; SCLC, small cell lung cancer; UNCA, antibodies binding to unclassified antigens